



Article Antimicrobial Activity of Some Steroidal Hydrazones

Maia Merlani¹, Nanuli Nadaraia¹, Lela Amiranashvili¹, Anthi Petrou², Athina Geronikaki^{2,*}, Ana Ciric³, Jasmina Glamoclija³, Tamara Carevic³ and Marina Sokovic³

- ¹ TSMU I. Kutateladze Institute of Pharmacochemistry, Tbilisi 0159, Georgia
- ² School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
- ³ Mycological Laboratory, Department of Plant Physiology, Institute for Biological Research "Siniša Stankovi'c", University of Belgrade, 11060 Beograd, Serbia
- * Correspondence: geronik@pharm.auth.gr; Tel.: +30-230-1997616

Abstract: Twelve steroid based hydrazones were in silico evaluated using computer program PASS as antimicrobial agents. The experimental evaluation revealed that all compounds have low to moderate antibacterial activity against all bacteria tested, except for *B. cereus* with MIC at a range of 0.37–3.00 mg/mL and MBC at 0.75–6.00 mg/mL. The most potent appeared to be compound **11** with MIC/MBC of 0.75/1.5 mg/mL, respectively. The evaluation of antibacterial activity against three resistant strains MRSA, *E. coli* and *P. aeruginosa* demonstrated superior activity of compounds against MRSA compared with ampicillin, which did not show bacteriostatic or bactericidal activities. All compounds exhibited good antifungal activity with MIC of 0.37–1.50 mg/mL and MFC of 1.50–3.00 mg/mL, but with different sensitivity against fungi tested. According to docking studies, 14-alpha demethylase inhibition may be responsible for antifungal activity. Two compounds were evaluated for their antibiofilm activity. Finally, drug-likeness and docking prediction were performed.

Keywords: hydrazones; ketosteroids; antimicrobial activity



Citation: Merlani, M.; Nadaraia, N.; Amiranashvili, L.; Petrou, A.; Geronikaki, A.; Ciric, A.; Glamoclija, J.; Carevic, T.; Sokovic, M. Antimicrobial Activity of Some Steroidal Hydrazones. *Molecules* **2023**, *28*, 1167. https://doi.org/10.3390/ molecules28031167

Academic Editors: Danuta Drozdowska and Robert Bucki

Received: 28 December 2022 Revised: 15 January 2023 Accepted: 17 January 2023 Published: 24 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

1. Introduction

The development of new antimicrobial agents is still attracting the interest of medicinal chemists since the resistance of bacterial pathogen strains is a major problem.

One of the reasons for the fast multiplication of bacteria is their ability to exchange genes with each other, leading to the development of resistance. On the other hand, the interest in the discovery of new antimicrobial agents is because during the past 30+ years, the FDA has approved only two new antimicrobial drugs: linezolid and daptomycin.

Despite the fact that many compounds have been synthesized and tested, their clinical use has been restricted due to the high risk of toxicity and pharmacokinetic deficiencies. Thus, the scientists have directed their efforts at developing novel approaches to antimicrobial therapy, aiming to overcome the resistance problem [1–4]. Another big problem is biofilm formation, which plays a crucial role in bacterial infection and antimicrobial resistance. There is increasing proof that cells in biofilms, on a biotic or abiotic surface, are 1000-fold more resistant to conventional drugs than planktonic cells [5,6]. The problem is that upon being established, biofilms become difficult to eliminate and as a result, chronic and persistent infections [7] appear. As reported in the literature [8,9], one of the main Gram-positive pathogens causing biofilm-associated infections is *Staphylococcus aureus*. Thus, another need is for the development of new agents that are able to inhibit *S. aureus* biofilm formation.

Hydrazones of different chemical classes possess diverse biological and pharmacological properties such as antimicrobial, anti-inflammatory, analgesic, antifungal, antitubercular, antiviral, anticancer, antiplatelet, antimalarial, anticonvulsant, cardio protective, anthelmintic, antiprotozoal, anti-trypanosomal, anti-schistosomiasis etc. [10–12]. Hydrazones contain two connected nitrogen atoms of different nature and a C-N double bond that is conjugated with a lone electron pair of the terminal nitrogen atom. These structural fragments are mainly responsible for the physical and chemical properties of hydrazones. The combination of thehydrazono group with other functional groups leads to compounds with a unique physical and chemical character [13]. It is noteworthy that there is an approved FDA drug with a hydrazone scaffold, namely levosimendan, a calcium sensitizer used in the management of acutely decompensated congestive heart failure (Figure 1).




Figure 1. Approved by FDA drug.

On the other hand, steroidal compounds are a class of bioactive substances playing a major role in living organisms with a wide representation in the natural world. Steroidal derivatives attracted the interests of scientists, especially medicinal chemists, due to their wide range of biological activities [10,13–15]. They are known to possess antimicrobial [16,17], antioxidant [17] and anticancer [17] activities. In the last few decades, the efforts have concentrated on rational modification of steroid molecules due to their lower toxicity, vulnerability to multi-drug resistance and high bioavailability to penetrate the cell wall and to be linked to nuclear and membrane receptors. Vollaro et al. [18] reported the investigation of the in vitro effect of pregnadiene-11-hydroxy-16 α ,17 α -epoxy-3,20-dione-1 (PYED-1) on biofilm formation.

Nowadays, a number of steroidal hydrazone derivatives have been developed and evaluated for their antimicrobial activity [19–24]. Among these hydrazones are some 5α -steroidal derivatives of the androstane and pregnane series with different functional groups.

Encouraged by these observations, and based on our previous work [25–27], herein we report the synthesis of two novel 5α -steroidal hydrazones and the evaluation of antimicrobial activity of newly and earlier synthesized compounds.


Thus, the purpose of our study was in silico and biological evaluation of the antimicrobial potential of twelve steroidal hydrazino derivatives, including action on the resistant strains.

2. Results and Discussion

2.1. Chemistry

In the continuation of our research on new bioactive N-containing 5α -steroids, ten steroidal hydrazine derivatives, that we synthesized earlier on the basis of steroidal ketones [25–29], and two new compounds were prepared and evaluated for their antibacterial and antifungal actions.

Isonicotinoylhydrazones 1–4 and 7 were synthesized from corresponding ketones androsta-1,4-diene-3,17-dione, and rosterone, epiandrosterone, allopregnanolone, 3α -hydroxy- 5α -androst-9(11)-en-17-one, by refluxing with hydrazide of isonicotinic acid in ethanol, respectively [25]. Thiosemicarbazones **5**, **6** and **8** were obtained from allopregnanolone, 3α -hydroxy- 5α -androst-9(11)-en-17-oneandandrosta-1,4-diene-3,17-dione by refluxing with thiosemicarbazide in ethanol, respectively [25]. *m*-Bromobenzoylhydrazones **10** [26] and **12** were synthesized from acetate epiandrosterone and androsterone, respectively, by refluxing with *m*-bromobenzohydrazide. *m*-Nitro hydrazones **9** [26] and **11** [29] were synthesized



similarly by refluxing the corresponding ketone with *m*-nitrobenzohydrazide. The synthesis of all these compounds is presented in Scheme 1.

Scheme 1. Synthetic route of substances (1–12): (a) isoniazide, EtOH, CH₃COOH, reflux 2 h; (b) thiosemicarbazide, EtOH, CH₃COOH, 2 h; (c) *m*-bromobenzohydrazide, EtOH, CH₃COOH; (d) *m*-nitrobenzohydrazide, EtOH, CH₃COOH, reflux, 5 h; (e) TsCl, pyridine, 0 °C, 20 h; (f) NaN₃, DMF, 100 °C, 5 h; (g) NaOH, MeOH, reflux 30 min; (h) ClCOCH₂C₆H₅, pyridine, benzene, reflux 6 h.

2.2. PASS Predictions

PASS prediction of antimicrobial activities was performed for previously synthesized compounds (1, 3–11), as well as for two new designed ones. The antibacterial activity was predicted only for two compounds with Pa values in the range 0.164–0.313, and antifungal activity for almost all compounds with Pa values in the range 0.143–0.470. The calculated Pa values for all compounds were less than 0.5, indicating their relative novelty compared to the structures of the compounds from the PASS training set [30]. This may be proof that the studied compounds have some features dissimilar from those of well-known antimicrobial agents, which may indicate their innovative potential.

2.3. Biological Evaluation

2.3.1. Antibacterial Activity

Synthesized compounds were tested for their antibacterial activity against a panel of nine bacteria species, using the microdilution method for the determination of minimal inhibitory and minimal bactericidal concentrations (MIC and MBC, respectively). As reference drugs, ampicillin and streptomycin were used. The antibacterial activity of tested compounds (Table 1) in general was low to moderate, except in some cases where it was good, with MIC ranging from 0.37 to 3.00 mg/mL and MBC at 0.75–9.00 mg/mL, presented in Table 1. The order of activity can be presented as follows: 11 = 12 > 4 = 5 > 3 > 1 > 6 > 7 > 10 > 8 > 9 > 2. Compound 11 appeared to be the most potent among those tested, with MIC and MBC of 0.75/1.5 mg/mL, respectively, but less than for both reference drugs. The most sensitive bacterium was found to be *B. cereus*, whereas *S. aureus* was the most resistant one.

Table 1. Antibacterial activity of	f compounds 1–12	(MIC/MBC in mg/	′mL).
------------------------------------	-------------------------	-----------------	-------

Compound	Compounds		MRSA	B.c	L.m.	E. coli	Rez E. coli	P.a.	Rez P.a.	S.Thy
	MIC	1.50	1.50	0.37	0.75	1.00	4.50	1.50	1.00	0.75
1	MBC	3.00	3.00	0.75	1.50	3.00	6.00	3.00	1.50	1.50
•	MIC	3.00	4.50	0.75	3.00	3.00	6.00	6.00	6.00	6.00
2	MBC	6.00	6.00	1.50	6.00	6.00	9.00	9.00	9.00	9.00
•	MIC	1.00	0.75	0.37	1.00	1.00	1.50	1.50	0.75	1.00
3	MBC	1.50	1.50	0.75	1.50	1.50	3.00	3.00	1.50	1.50
4	MIC	0.75	3.00	0.37	0.75	1.50	1.50	0.75	0.75	0.75
4	MBC	1.50	6.00	0.75	1.50	3.00	3.00	1.50	1.50	1.50
-	MIC	0.75	1.50	0.37	0.75	1.50	1.50	0.75	1.00	0.75
5	MBC	1.50	3.00	0.75	1.50	3.00	3.00	1.50	1.50	1.50
6	MIC	0.75	1.50	0.37	1.50	1.50	0.75	3.00	1.50	1.50
6	MBC	1.50	3.00	0.75	3.00	3.00	1.50	6.00	3.00	3.00
7	MIC	0.75	1.50	0.50	1.50	1.50	0.75	3.00	1.50	1.50
7	MBC	1.50	3.00	0.75	3.00	3.00	1.50	6.00	3.00	3.00
8	MIC	1.50	1.50	0.37	1.50	1.50	1.50	3.00	1.50	1.50
0	MBC	3.00	3.00	0.75	3.00	3.00	3.00	6.00	3.00	3.00
9	MIC	1.50	3.00	1.50	0.75	3.00	6.00	1.50	3.00	3.00
9	MBC	3.00	6.00	3.00	1.50	6.00	9.00	3.00	6.00	6.00
10	MIC	1.50	3.00	1.50	0.75	3.00	6.00	1.50	1.50	0.75
10	MBC	3.00	6.00	3.00	1.50	6.00	9.00	3.00	3.00	1.50
11	MIC	0.75	1.50	0.75	0.75	0.75	1.50	0.75	0.75	0.75
11	MBC	1.50	3.00	1.50	1.50	1.50	3.00	1.50	1.50	1.50
12	MIC	0.75	1.50	0.75	0.75	0.75	1.50	0.75	0.75	0.75
14	MBC	1.50	3.00	1.50	1.50	1.50	3.00	1.50	1.50	1.50
Ampicillin	MIC	0.10	-	0.10	0.15	0.15	0.20	0.30	0.20	0.10
mpremm	MBC	0.15	-	0.15	0.30	0.20	-	0.50	-	0.20
Streptomycin	MIC	0.10	0.10	0.025	0.15	0.10	0.05	0.10	0.10	0.10
Gacptomycm	MBC	0.20	-	0.050	0.30	0.20	0.10	0.20	0.20	0.20

The structure–activity relationship studies revealed that the presence of 3-nitrobenzohy drazide at position 17 of 3α -hydroxy- 5α -androstan-17-one **11** is beneficial for antibacterial activity. The replacement of the nitro group in the benzene ring by Br led to compound **12** having the same good influence as the previous one, on activity. The replacement of the substituted benzene ring by isonicotinoylhydrazide, and 3α -hydroxy- 5α -androstan-17-one by 3α -hydroxy- 5α -pregnan-20-one, resulted in compound **4** with slightly lower activity. It is interesting to notice that the presence of thethiosemicarbazide substituent at position 20 (**5**) of the steroid ring, in place of isonicotinoylhydrazide (**4**) as the substituent in position 20, exhibited the same activity as compound **4**. Replacement of hydroxy group in position 3 by phenylacetoxy (**3**) decreased the antibacterial activity more, while replacement by theazide group (**2**) was detrimental.

The evaluation of antibacterial activity of these compounds against three resistant strains, MRSA, *E. coli* and *P. aeruginosa* revealed that compounds were more potent against MRSA than ampicillin, which did not show bacteriostatic or bactericidal activity, while against the two other resistant strains, it did not show bactericidal activity. The order of activity of the tested compounds against resistant strains can be presented as 6 = 7 > 1 > 3 > 4 > 11 = 12 > 5 > 8 > 10 > 9 > 2, with compounds 6 and 7 being the most potent (MIC/MBC at 0.75–1.50 mg/mL and 1.50–3.00 mg/mL, respectively). It should be mentioned that compounds 3–5, 8–12 did not show any activity against the resistant *E. coli* strain. It is interesting to notice that compounds 6 and 7 were more potent against resistant *E. coli* than *E. coli* strains, while the opposite was observed for compounds 1 and 2. On the other hand, compounds 1,3,6,7 and 8 exhibited better activity against *P. aeruginosa* and against resistant *P. aeruginosa*, while compounds 2,4,10–12 demonstrated the same activity against the resistant *P. aeruginosa* strain than against two other resistant strains, being less potent than the reference drug streptomycin.

In the case of structure–activity relationship studies against resistant strains, it was found that the presence of athiosemicarbazide substituent (6) as well as anisonicotinoylhydrazide one (7) in position 17 of 3α -hydroxy- 5α -androst-9(11)-en-17-one was favorable for the activity against resistant strains.

Finally, it should be mentioned that compounds tested have different behavior against ATCC and resistant strains. The only common behavior against both strains was observed for compound **2**, which demonstrated a negative effect on antibacterial activity in both cases.

2.3.2. Antifungal Activity

Compounds were also tested for their antifungal activity against six fungal strains using the microdilution method, and ketoconazole as well as bifonazole were used as reference drugs. The results are presented in Table 2. In general, compounds showed moderate to good activity with MIC and MFC in the range of 0.37–3.00 mg/mL and 0.50–6.00 mg/mL, respectively. The order of activity of tested compounds can be presented as follows: 7 = 8 > 3 > 1 = 9 > 12 > 11 > 6 > 10 > 5 > 2 > 4. The best activity was achieved for 3α -hydroxy- 5α -androst-9(11)-en-17-one isonicotinoylhydrazone (7), with MIC/MFC of 0.37/0/75 mg/mL, respectively, as well as for compound 8. The lowest antifungal effect was observed for compound 4, with an MIC ranging from 0.75 to 3.00 mg/mL and MFC from 1.5 to 6.0 mg/mL. It should be noticed that compounds 7 and 8 showed the best potential against all fungi tested (MIC at 0.37 mg/mL), while compound 3 demonstrated the same effect against all fungi except for *C. albicans*. On the other hand, compounds 9 and 12 also showed the same good activity with previous ones against A. fumigatus, T. viride, C. albicans and A. fumigatus, A. niger, T. viride, respectively. Ketoconazole exhibited antifungal potential at MIC in the range 0.2–1.0 mg/mL and MFC of 0.3–2.0 mg/mL, while bifonazole at MIC 0.10–0.20 mg/mL and MFC at 0.2–0.3 mg/mL, respectively. All compounds showed higher activity than ketoconazole (MIC/MFC of 1.0/1.5 mg/mL) against *T. viride*, the most sensitive fungal. However, it is more important that almost all compounds, except for **11** and **12**, were more potent than ketoconazole against *C. albicans*—the most resistant to

Сотро	unds	A.fu	A.n.	T.v.	P.f.	P.v.c.	C.a.
	MIC	0.75	0.75	0.37	0.75	0.37	0.37
1	MFC	1.50	1.50	0.75	1.50	0.75	0.75
•	MIC	1.50	1.50	1.50	1.50	3.00	0.37
2	MFC	3.00	3.00	3.00	3.00	6.00	0.75
2	MIC	0.37	0.37	0.37	0.37	0.37	0.75
3	MFC	0.75	0.75	0.75	0.75	0.75	1.50
4	MIC	1.50	3.00	3.00	3.00	3.00	0.75
4	MFC	3.00	6.00	6.00	6.00	6.00	1.50
5	MIC	1.50	1.50	1.50	1.50	0.75	0.75
5	MFC	3.00	3.00	3.00	3.00	1.50	1.50
6	MIC	1.50	1.50	1.50	0.75	0.75	0.75
0	MFC	3.00	3.00	3.00	1.50	1.50	1.50
7	MIC	0.37	0.37	0.37	0.37	0.37	0.37
/	MFC	0.75	0.75	0.75	0.75	0.75	0.75
8	MIC	0.37	0.37	0.37	0.37	0.37	0.37
0	MFC	0.75	0.75	0.75	0.75	0.75	0.75
9	MIC	0.37	0.75	0.37	0.75	0.75	0.37
9	MFC	0.75	1.50	0.75	1.50	1.50	0.75
10	MIC	0.37	1.50	0.75	1.50	3.00	0.37
10	MFC	0.50	3.00	1.50	3.00	6.00	0.75
11	MIC	0.75	1.50	0.75	0.75	1.50	1.50
11	MFC	1.50	3.00	1.50	1.50	3.00	3.00
12	MIC	0.37	0.37	0.37	0.75	1.50	1.50
14	MFC	0.50	0.50	0.75	1.50	3.00	3.00
Ketoconazole	MIC	0.20	0.20	1.00	0.20	0.20	1.00
Kelocollazole	MFC	0.50	0.50	1.50	0.50	0.30	2.00
Bifonazole	MIC	0.15	0.15	0.15	0.20	0.10	0.20
	MFC	0.20	0.20	0.20	0.25	0.20	0.30

our compounds and the deathliest fungal, responsible together with filaments fungal *A*. *fumigatus* for 85–90% of deaths.


Table 2. Antifungal activity of compounds 1–12 (MIC/MBC in mg/mL).

According to the structure–activity relationship studies, the presence of isonicotinoylhydrazide (7) in position 17 of 3 α -hydroxy-5 α -androst-9(11)-en-17-one core and dithiosemicarbazide of androst-1,4-dien-3,17-dione moiety (8) have a positive influence on antifungal activity. Replacement of 3 α -hydroxy-5 α -androst-9(11)-en-17-one core by 3 β -phenylacetoxy-5 α -androstan-17-one and introduction to position 17 isonicotinoylhydrazide substituent led to compound 3 havingdecreased activity, which decreased more by introduction of a 3 β -azido-5 α -androstan-17-one moiety (2) instead of 3 β -phenylacetoxy-5 α -androstan-17-one (3). The same influence on antifungal activity resulted from the presence of *m*nitrobenzoylhydrazide in 3 β -acetoxy-5 α -androstan-17-one core. The replacement of the 3 α -hydroxy-5 α -androst-9(11)-en-17-one core of compound 7 by 3 α -hydroxy-5 α -pregnan-20-one (4) and thiosemicarbazide substituent at position 20 by isonicotinoylhydrazide (4) weredetrimental for antifungal activity. In general, 3 α -hydroxy-5 α -androstan-17-one isonicotinoylhydrazone 2 were not favorable for antifungal activity.

2.3.3. Inhibition of Biofilm Formation


After the observation of the antifungal activities of compounds, antibiofilm activities were assessed. We observed that compounds **1** and **8** possessed higher antifungal activity against *C. albicans* and all tested micro fungi than other used compounds. The strain used for the antibiofilm assay was *C. albicans*. Incubation with compounds **1** and **8** hasreduced the ability of *C. albicans* (Figures 2 and 3) to attach to the surface and begin the process of biofilm formation. A concentration equal to the previously determined MIC has reduced

the biofilm biomass by 33% and 15% for compounds **1** and **8**, respectively. When applied in 0.5 and 0.25 MIC concentrations of compound **1**, inhibition percentages were almost the same, about 18% (Figure 3). The reference drug, Ketoconazole, possessed better biofilm activity than the compounds, reducing the biofilm biomass by 50%, 47% and 25% for MIC concentrations 0.5 MIC and 0.25 MIC, respectively (Figure 2).



C. albicans ATCC 10231

Figure 2. Percentages of inhibition of *C. albicans* ATCC 10231 biofilm formation by compound **1** and Ketoconazole.






Figure 3. Percentages of inhibition of *C. albicans* ATCC 10231 biofilm formation by compound **8** and Ketoconazole.

Even twice as low concentrations (0.5 MIC) of compound 8 limited the biofilm forming ability and induced more than 16% inhibition in *C. albicans*. The impact on the fungal biofilm was less profound and the 0.25 MIC concentration of 8 was able to reduce the biofilm formation byless than 5% (Figure 3).

2.4. Docking to Antifungal Targets

In order to investigate the possible mechanism of antifungal activity of compounds, all of them along with the reference drug ketoconazole were docked to lanosterol 14α -demethylase of *C. albicans* and DNA topoisomerase IV. The results are presented in Table 3.

	Est. Binding Energy (kcal/mol)		Residues Involved in	Residues Involved in	Residues Involved in	
Comp.	DNA TopoIV 1S16	CYP51 of C. albicans 5V5Z	H-bond Formation	Hydrophobic Interactions	Aromatic Interactions	Interactions with HEM601
1	-4.11	-8.52	Tyr132	Tyr118, Thr122, Thr311, Phe380, Met508, Hem601	Hem601	Hydrophobic, aromatic
2	-3.31	-6.38	-	Tyr118, Thr311, Leu376, Hem601	-	Hydrophobic
3	-3.58	-9.04	Met508	Tyr118, Thr122, Phe228, Phe233, Thr311, Leu376, Phe380, Met508, Hem601	Hem601	Hydrophobic, aromatic
4	-1.77	-6.01	-	Tyr118, Leu376, Met508, Hem601	-	Hydrophobic
5	-2.47	-6.80	-	Tyr118, Tyr122, Leu376, Met508, Hem601	Tyr118	Hydrophobic
6	-4.20	-7.32	-	Tyr118, Tyr122, Thr311, Leu37, Hem601	Tyr118	Hydrophobic
7	-3.18	-9.86	Tyr132	Tyr118, Leu121, Thr311, Met508, Hem601	Hem601	Hydrophobic, aromatic
8	-2.54	-10.23	Tyr64	Tyr118, Thr122, Ile131, Tyr132, Leu376, Met508, Hem601	-	Hydrophobic, Fe binding
9	-3.61	-8.48	Tyr132	Tyr118, Leu121, Thr122, Thr311, Met508, Hem601	Hem601	Hydrophobic, aromatic
10	-1.38	-7.11	-	Tyr118, Thr311, Met508, Hem601	Tyr118	Hydrophobic
11	-2.47	-7.55	Tyr118	Tyr118, Leu121, Met508, Hem601	-	Hydrophobic
12	-1.28	-8.02	Tyr118	Tyr118, Tyr122, Thr311, Met508, Hem601	Hem601	Hydrophobic, aromatic
ketoconazole	-	-8.93	Tyr64	Tyr118, Ile131, Tyr132, Leu300, Ile304, Leu376, Met508, Hem601	Hem601	Hydrophobic, aromatic

Table 3. Molecular docking free binding energies (kcal/mol) to antifungal targets.

Based on docking studies, all compounds bind to the CYP51 Ca enzyme similarly to the reference drug ketoconazole (Figure 4). The most active compound 8 binds to the Fe of the heme and interacts hydrophobically and aromatically with the heme. Additionally, compound 8 forms a hydrogen bond between the oxygen atom of the C=O group and the side-chain hydrogen of Tyr64. Hydrophobic interactions were also detected between residues I Tyr118, Thr122, Ile131, Tyr132, Leu376, Met508 and the compound (Figure 5). Ketoconazole also forms aromatic and hydrophobic interactions with the heme group. It has been shown, however, that compound 8 forms a more stable complex with the enzyme, possibly due to its interaction with heme's iron. It is likely that this is the reason why this compound has a better antifungal effect than ketoconazole.




Figure 4. Docked conformation of ketoconazole in lanosterol 14α -demethylase of *C. albicans* (CYP51_{ca}).





Figure 5. (A) Superposition of compound 8 (magenta) and ketoconazole (blue) in lanosterol 14α -demethylase of *C. albicans* (CYP51_{ca}). (B) Docked conformation of the most active compound 8 in lanosterol 14α -demethylase of *C. albicans* (CYP51_{ca}). Red dotted arrows indicate H-bond, blue arrows aromatic interactions and yellow spheres hydrophobic interactions.

The superposition of compound **3** and ketoconazole (Figure 6) explains its good antifungal activity. Similar to ketoconazole, compound **3** inserts the binding site of the enzyme, forming an additional hydrogen bond with residue Met508. In addition, it exhibits the same hydrophobic and aromatic interactions with the heme group as ketoconazole, which explains its good inhibition profile.

2.5. Drug-Likeness

All tested compounds were evaluated for their drug-likeness and bioavailability scoresand the results are presented in Table 4. According to the prediction, the bioavailability score for most of the compounds was about 0.55, except for compounds **3**, **9**, **10** and **12** with 0.17 values. Despite these compounds exhibiting two violations of Lipinski's rule of



five, they have excellent drug-likeness scores ranging from 0.74 to 1.54. Thus, it can be concluded that they have good oral bioavailability and drug-likeness profile (Figure 7).

Figure 6. (A) Superposition of compound **3** (yellow) and ketoconazole (blue) in lanosterol 14α demethylase of *C. albicans* (CYP51_{ca}). (B) Docked conformation of compound **3** in lanosterol 14α demethylase of *C. albicans* (CYP51_{ca}). Red dotted arrows indicate H-bond, blue arrows aromatic interactions and yellow spheres hydrophobic interactions.

No	MW	Number of HBA ^a	Number of HBD ^b	Log P _{o/w} (WLOGP) ^c	Log S ^d	TPSA ^e	Lipinski	Bioavailability Score	Drug- Likeness Model Score
1	522.64	6	2	5.09	Moderately soluble	108.70	0	0.55	1.09
2	448.60	6	1	6.28	Moderately soluble	104.10	0	0.55	1.30
3	541.72	5	1	6.75	Moderately soluble	80.65	2 violations: MW > 500, MLOGP > 4.15	0.17	1.54
4	423.59	4	2	3.75	Moderately soluble	74.58	0	0.55	1.48
5	405.64	2	3	4.61	Moderately soluble	102.73	0	0.55	0.71
6	375.57	3	2	3.44	Moderately soluble	102.73	0	0.55	0.74
7	407.55	4	2	4.49	Moderately soluble	74.78	0	0.55	1.29
8	430.66	2	4	3.10	Soluble	165.00	0	0.55	0.78

 Table 4. Drug-likeness predictions of tested compounds.

No	MW	Number of HBA ^a	Number of HBD ^b	Log P _{o/w} (WLOGP) ^c	Log S ^d	TPSA ^e	Lipinski	Bioavailability Score	Drug- Likeness Model Score
9	509.64	6	1	6.05	Poorly soluble	113.58	2 violations: MW > 500, MLOGP > 4.15	0.17	0.98
10	543.54	4	1	6.90	Poorly soluble	67.76	2 violations: MW > 500, MLOGP > 4.15	0.17	1.18
11	467.60	5	2	5.47	Moderately soluble	107.51	0	0.55	0.85
12	501.50	3	2	6.33	Moderately soluble	61.69	2 violations: MW > 500, MLOGP > 4.15	0.17	1.07

Table 4. Cont.

^a number of hydrogen bond acceptors; ^b number of hydrogen bond donors; ^c lipophilicity; ^d Water solubility (SILICOS-IT [S = Soluble]); ^e topological polar surface area (Å²).




Figure 7. Drug-likeness model and bioavailability radar of the compounds **3** and **4**. The pink area represents the optimal range for each property for oral bioavailability, (Lipophilicity (LIPO): XLOGP3 between -0.7 and +5.0, Molecular weight (SIZE): MW between 150 and 500 g/mol, Polarity (POLAR) TPSA between 20 and 130 Å², Solubility (INSOLU): log S not higher than 6, Saturation (INSATU): fraction of carbons in the sp³ hybridization not less than 0.25 and Flexibility (FLEX): no more than 9 rotatable bonds.

3. Materials and Methods

3.1. Chemistry—General Information

All commercially available reagents, isonicotinic acid hydrazide, *m*-bromobenzoic acid hydrazide, *m*-nitrobenzoic acid hydrazide and androsta-1,4-diene-3,17-dione were of analytical grade and used without further purification (all from Sigma Aldrich, Schnelldorf, Germany).

¹H NMR and ¹³C NMR spectra were recorded using DMSO-d₆ or CDCl₃ as a solvent at 22 °C with a Bruker AC 400 instrument. IR spectra were recorded using a JASCO FT/IR-4600 spectrometer. Mass spectra were obtained on an HPLC-APCIMS (positive mode)-Agilent 1100 Series with an Inertsil PREP-ODS column (6.0×250 mm) and elution of steroids by H₂O–MeCN (20:80). The melting points were recorded on a Gallenkamp apparatus and are uncorrected. The IR, ¹HNMR and ¹³C NMR spectra can be found in Supplementary Materials.

 3β -Phenylacetoxy- 5α -androstan-17-one isonicotinoylhydrazone (3)

A mixture of 3β-phenylacetoxy-5α-androstan-17-one (1 g, 2.44 mmol), isonicotinic acid hydrazide (0.39 g, 2.92 mmol) and acetic acid (1 mL) in ethanol (20 mL) was boiled for 2 h and cooled to room temperature. The resulting precipitate was filtered off, washed with water and crystallized from ethanol. Yield 75%, m.p. 180–182 °C. IR(KBr): 3169, 1729, 1639, 1598, 1548, 1494, 1452, 1132, 1010, 928, 841 cm⁻¹. ¹H NMR (400 MHz, CDCl₃, δ , ppm, J/Hz): δ , 0.89 and 1.00 (6H, s, 18-CH₃, 19-CH₃), 3.62 (2H, s, CH₂C₆H₅), 4.75 (1H, m, H-3), 7.28–7.37 (5H, m, C₆H₅), 7.65–7.80 (2H, H-Pr), 8.50 (1H, s, NHCO), 8.75–8.79 (2H, dd, J = 5.8, J = 2.2, H-Pr). ¹³C NMR spectrum (100 MHz, CDCl₃, δ , ppm): 12.3, 16.9, 20.7, 23.5, 25.3, 26.2, 27, 4, 28.3, 31.4, 33.9, 34.9, 35.7, 36.7, 41.8, 44.8, 44.9, 45.5, 53.4, 54.5, 74.0, 121.0, 124.0, 126.9, 128.5, 129.2, 134.4, 140.7, 141.1, 149.6, 150.7, 167.6, 168.1, 171.2, 174.0.

 3α -Hydroxy- 5α -androstan-17-one *m*-bromobenzoylhydrazone (12)

A mixture of 3α-hydroxy-5α-androstan-17-one (0.05 g, 0.14 mmol), m-bromobenzoic acid hydrazide (0.04 g, 0.2 mmol) and 0.1 mL acetic acid was refluxed in ethanol for 5 h. The resulting precipitate was filtered off, washed with water and crystallized from ethanol. Yield 80%, m.p. 266–268 °C. IR(KBr): 3465, 3360, 1675, 1643, 1609, 1565, 1518, 1363, 1259, 1003, 930, 890, 606 cm⁻¹. ¹H NMR (400 MHz, DMSO-d₆, δ , ppm, J/Hz): δ , 0.78 (3H, s, 18-CH₃), 0.86 (3H, s, 19-CH₃), 2.36–2.60 (2H, m, H-16), 4.47 (1H, s, H-3), 7.44 (1H, m, H-Ar), 7.75 (2H, m, H-Ar), 7.95 (1H, s, H-Ar), 10.34 (1H, s, NHCO). ¹³C NMR spectrum (100 MHz, DMSO-d₆, δ , ppm J/Hz): 12.0, 16.7, 20.2, 22.7, 26.7, 28.1, 30.8, 31.2, 34.5, 35.0, 36.4, 37.9, 44.3, 44.5, 52.7, 53.9, 69.1, 121.4, 126.6, 130.2, 133.8, 136.4, 150.4, 161.8, 175.1.

3.2. In Vitro Evaluation of Antimicrobial Activity

The following Gram-negative bacteria: *Escherichia coli* (ATCC 35210), *Salmonella* Typhimurium (ATCC 13311), *Pseudomonas aeruginosa* (ATCC 27853) as well as Gram-positive bacteria: *Listeria monocytogenes* (NCTC 7973), *Bacillus cereus* (clinical isolate) and *Staphylococcus aureus* (ATCC 6538) were used. Resistant strains used were Methicillin resistant *S. aureus* (IBRS MRSA 011), resistant *E. coli* (IBRS E003) and resistant *P. aeruginosa* (IBRS P001) obtained as described in the previous paper [31]. The organisms were obtained from the Mycological Laboratory, Department of Plant Physiology, Institute for Biological Research "Siniša Stankovic", National Institute of Republic of Serbia, Belgrade, Serbia.

The antifungal activity of all investigated samples was tested on strains obtained from the Mycological Laboratory, Department of Plant Physiology, Institute for Biological Research "Sinisa Stankovic", National Institute of Republic of Serbia, Belgrade, Serbia. The following fungi *Aspergillus fumigatus* (ATCC 1022), *Aspergillus niger* (ATCC 6275), *Trichoderma viride* (IAM 5061), *Penicillium funiculosum* (ATCC 36839), *P. verrucosum var. cyclopium* (food isolates) and *Candida albicans* (ATCC 10231) were tested. The detailed explanation is given in our previous papers [32,33].

Commercial antibiotics, ampicillin and streptomycin, and fungicides, bifonazole and ketoconazole, were used as positive controls. EtOH 30% was used as a negative control. All experiments were performed in duplicate and repeated three times.

The minimum inhibitory (MIC) and minimum bactericidal/fungicidal (MBC/MFC) concentrations were determined by the modified microdilution method, as previously reported [34,35].

Inhibition of Biofilm Formation

The potential of compounds to inhibit biofilm formation was investigated as previously described, with some modifications [36] *C. albicans* ATCC 10231 was incubated in 96-well microtiter plates with an adhesive bottom (Sarstedt, Germany), with MIC and sub-MIC concentrations of tested compounds/referent drug in YPD medium at 37 °C for 24 h. Afterwards, wells were washed thrice with sterile PBS (Phosphate buffered saline, pH 7.4) and biofilms were fixed with methanol for 20 min. Then, methanol was removed and stained with 0.1% crystal violet (Bio-Merieux, France) for 30 min. The plate was slowly washed, air dried and 96% ethanol (Zorka, Serbia) was added to dissolve bounded crystal violet. The absorbance (620 nm) was read on a MultiskanTM FC Microplate Photometer, Thermo ScientificTM. Lastly, the percentage of inhibition of biofilm formation was calculated by the formula:

Percentage of inhibition = $((A_{620(control)} - A_{620sample})/A_{620control})) \times 100$

3.3. Docking

AutoDock 4.2[®] software was used for the in silico studies and a detailed procedure is reported in our previous paper [37].

3.4. Drug-Likeness

Drug-likeness [38] scores of compounds were predicted using the Molsoft software and SwissADME program (http://swissadme.ch, accessed on 19 October 2022) via the ChemAxon's Marvin JS structure drawing tool [39].

4. Conclusions

This work presents the synthesis of two new steroid derivatives and the study of antibacterial and antifungal activities together with previously synthesized compounds against a panel of bacterial and fungal pathogens of twelve steroid derivatives, two of which are new. The antibacterial activity of tested compounds was low to moderate with minimal inhibitory concentration being 0.37–1.5 mg/mL and minimal bactericidal being 1.5–3.0 mg/mL, except against *B. cereus* which was good. The antibacterial activity against resistant strains MRSA, E. coli and P. aeruginosa was superior against MRSA than ampicillin, which did not show bacteriostatic or bactericidal activity, while against the two other strains, it did not show bactericidal activity. All compounds exhibited moderate to good antifungal potency with MIC and MFC in the range of 0.37–3.00 mg/mL and 0.50–6.00 mg/mL, respectively. Compound 7 demonstrated the best activity among all tested with MIC/MFC of 0.37/0/75 mg/mL, respectively. The most sensitive fungal to compounds tested was T. viride, while C. albicans was the most resistant one. Despite this, almost all compounds except for **11** and **12** were more potent than ketoconazole against *C. albicans*, the deathiest fungal. Antibiofilm activity assessed for the two most potent compounds 1 and 8 in concentrations of MIC, 0.5 MIC and 0.25 MIC revealed that it was lower (33 and 15%, respectively, in concentration of MIC) than that of ketoconazole. According to docking results, it seems that the inhibition of CYP51 reductase is responsible for the antifungal activity of the compounds. All compounds showed good drug-likeness scoresin the range of 0.71–1.54. Three compounds showed two violations to the Lipinski rule.

Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/molecules28031167/s1; Figure S1: ¹³C NMR spectrum of compound **1** in DMSO-d6; Figure S2: ¹H NMR spectrum of 3β-azido-5α-androstan-17-one isonicotinoylhydrazone (compound **2**) in CDCl₃; Figure S3: ¹³C NMR spectrum of 3β-azido-5α-androstan-17-one isonicotinoylhydrazone (compound **2**) in CDCl₃; Figure S4: IR spectrum of 3β -phenylacetoxy-5αandrostan-17-one isonicotinoylhydrazone (compound 3) in KBr; Figure S5: ¹H NMR spectrum of 3β -phenylacetoxy- 5α -androstan-17-one isonicotinoylhydrazone (compound **3**) in CDCl₃; Figure S6: 13 C NMR spectrum of 3 β -phenylacetoxy-5 α -androstan-17-one isonicotinoylhydrazone (compound 3) in CDCl₃; Figure S7: MS spectrum of 3β -phenylacetoxy- 5α -androstan-17-one isonicotinovlhydrazone (compound 3); Figure S8: ¹³C NMR spectrum of compound 4 in d₆-DMSO; Figure S9: ¹H NMR spectrum of 3α -hydroxy- 5α -pregnan-20-one thiosemicarbazone (compound 5) in d₆-DMSO; Figure S10: ¹³C NMR spectrum of 3α -hydroxy- 5α -pregnan-20-one thiosemicarbazone (compound 5) in d₆-DMSO; Figure S11: 13 C NMR spectrum of compound **6** in d₆-DMSO; Figure S12: 11 H NMR spectrum of 3α -hydroxy- 5α -androst-9(11)-en-17-one isonicotinoylhydrazone (compound 7) in d₆-DMSO; Figure S13: ¹³C NMR spectrum of 3α -hydroxy- 5α -androst-9(11)-en-17-one isonicotinoylhydrazone (compound 7) in d₆-DMSO; Figure S14: ¹³C NMR spectrum of androsta-1,4-diene-3,17-dione dithiosemicarbazone (compound 8) in d₆-DMSO; Figure S15: 13 C NMR spectrum of 3 β -acetoxy-5 α androstan-17-one *m*-nitrobenzoylhydrazone (compound **9**) in d₆-DMSO; Figure S16: ¹³C NMR spectrum of 3β -acetoxy- 5α -androstan-17-one *m*-bromobenzoylhydrazone (compound **10**) in d₆-DMSO; Figure S17: ¹H NMR spectrum of 3α -hydroxy- 5α -androstan-17-one *m*-nitrobenzoylhydrazone (compound 11) in d₆-DMSO; Figure S18: ¹³C NMR spectrum of 3α -hydroxy- 5α -androstan-17-one *m*-nitrobenzoylhydrazone (compound **11**) in d₆-DMSO; Figure S19: IR spectrum of 3α -hydroxy- 5α androstan-17-one *m*-bromobenzoylhydrazone (compound **12**) in KBr; Figure S20: ¹H NMR spectrum of 3α -hydroxy- 5α -androstan-17-one *m*-bromobenzoylhydrazone (compound **12**) in d₆-DMSO; Figure S21: ¹³C NMR spectrum of 3α -hydroxy- 5α -androstan-17-one *m*-bromobenzoylhydrazone (compound 12) in d₆-DMSO; Figure S22: Fragment of 13 C NMR spectrum 3 α -hydroxy-5 α -androstan-17-one *m*-bromobenzoylhydrazone (compound 12) in d₆-DMSO; Figure S23: MS spectrum of 3αhydroxy- 5α -androstan-17-one *m*-bromobenzoylhydrazone (compound 12).

Author Contributions: Conceptualization, A.G., M.M.; methodology, L.A., N.N.; software, A.P.; investigation, M.M., A.C., J.G., T.C.; data curation, A.G., A.C.; writing—original draft preparation, A.G., M.M.; writing—review and editing, A.G., A.C.; visualization, A.P.; supervision, A.G., M.M. funding acquisition, M.S. All authors have read and agreed to the published version of the manuscript.

Funding: The authors thank the Serbian Ministry of Education, Science and Technological Development, for the financial support (grant number 451-03-68/2022-14/200007).

Institutional Review Board Statement: IR, ¹HNMR, ¹³C NMR, spectra.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Not applicable.

References

- 1. Coates, A.R.M.; Hu, Y. Novel approaches to developing new antibiotics for bacterial infections. *Br. J. Pharmacol.* 2007, 152, 1147–1154. [CrossRef] [PubMed]
- Spellberg, B.; Bartlett, J.; Wunderink, R.; Gilbert, D.M. Novel approaches are needed to develop tomorrow's antibacterial therapies. *Am. J. Respir. Crit. Care Med.* 2015, 191, 135–140. [CrossRef] [PubMed]
- 3. Cataldo, M.A.; Granata, G.; Petrosillo, N. Clostridium difficile infection: New approaches to prevention, non-antimicrobial treatment, and stewardship. *Expert Rev. Anti Infect. Ther.* **2017**, *15*, 1027–1040. [CrossRef] [PubMed]
- Hughes, G.; Webber, M.A. Novel approaches to the treatment of bacterial biofilm infections. Br. J. Pharmacol. 2017, 174, 2237–2246. [CrossRef]
- Parsek, M.R.; Singh, P.K. Bacterial biofilms: An emerging link to disease pathogenesis. *Annu. Rev. Microbiol.* 2003, 57, 677–701. [CrossRef]
- Verderosa, A.D.; Totsika, M.; Fairfull-Smith, K.E. Bacterial Biofilm Eradication Agents: A Current Review. Front. Chem. 2019, 28, 824–841. [CrossRef] [PubMed]
- 7. Bjarnsholt, T. The role of bacterial biofilms in chronic infections. *APMIS Suppl.* **2013**, *136*, 1–51. [CrossRef] [PubMed]
- 8. Tong, S.Y.; Davis, J.S.; Eichenberger, E.; Holland, T.L.; Fowler, V.G.J. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. *Clin. Microbiol. Rev.* **2015**, *28*, 603–661. [CrossRef] [PubMed]
- 9. Otto, M. Staphylococcal infections: Mechanisms of biofilm maturation and detachment as critical determinants of pathogenicity. *Annu. Rev. Med.* **2013**, *64*, 175–188. [CrossRef]

- Verma, G.; Marella, A.; Shaquiquzzaman, M.; Akhtar, M.; Ali, M.R.; Alam, M.M. A review exploring biological activities of hydrazones. J. Pharm. Bioallied Sci. 2014, 6, 69–80.
- 11. Rollas, S.; Küçükgüzel, Ş.G. Biological Activities of Hydrazone Derivatives. Molecules 2007, 12, 1910–1939. [CrossRef] [PubMed]
- 12. Belskaya, N.P.; Dehaen, W.; Bakulev, V.A. Synthesis and properties of hydrazones bearing amide, thioamide and amidine functions. *Arch. Org. Chem.* **2010**, *1*, 275–332. [CrossRef]
- Tantawy, M.A.; Nafie, M.S.; Elmegeed, G.A.; Ali, I.A. Auspicious role of the steroidal heterocyclic derivatives as a platform for anti-cancer drugs. *Bioorg. Chem.* 2017, 73, 128–146. [CrossRef] [PubMed]
- 14. Ericson-Neilsen, W.; Kaye, A.D. Steroids: Pharmacology, complications, and practice delivery issues. Ochsner J. 2014, 14, 203–207.
- Krstić, N.M.; Bjelaković, M.S.; Pavlović, V.D.; Robeyns, K.; Juranić, Z.D.; Matić, I.; Novakovic, I.; Sladić, D.M. New androst-4-en-17-spiro-1, 3, 2-oxathiaphospholanes. Synthesis, assignment of absolute configuration and in vitro cytotoxic and antimicrobial activities. *Steroids* 2012, 77, 558–565. [CrossRef]
- 16. Hryniewicka, A.; Malinowska, M.; Hauschild, T.; Pieczul, K.; Morzycki, J.W. Synthesis and antimicrobial properties of steroidbased imidazolium salts. *J. Steroid. Biochem. Mol. Biol.* 2019, *189*, 65–72. [CrossRef]
- Farhan, A.M.; Alshamusi, Q.K.; Jebur, M.H. Synthesis of steroid bearing heterocyclic derivatives and biological activity. Review 2014–2020. J. Phys. Conf. Ser. 2021, 1853, 01205.
- Vollaro, A.; Esposito, A.; Esposito, E.P.; Zarrilli, R.; Guaragna, A.; De Gregorio, E. PYED-1 Inhibits Biofilm Formation and Disrupts the Preformed Biofilm of *Staphylococcus aureus*. *Antibiotics* 2020, 9, 240. [CrossRef]
- 19. Mistry, S.; Singh, A.K. Synthesis and in vitro antimicrobial activity of new steroidal hydrazone derivatives. *FJPS* **2022**, *8*, 7. [CrossRef]
- Popiołek, Ł. Hydrazide–hydrazones as potential antimicrobial agents: Overview of the literature since 2010. *Med. Chem. Res.* 2016, 26, 287–301. [CrossRef]
- Visbal, G.; San-Blas, G.; Maldonado, A.; Alvarez-Aular, A.; Capparelli, M.V.; Murgich, J. Synthesis, in vitro antifungal activity and mechanism of action of four sterol hydrazone analogues against the dimorphic fungus Paracoccidioides brasiliensis. *Steroids* 2011, 76, 1069–1081. [CrossRef] [PubMed]
- Gan, C.; Cui, J.; Su, S.; Lin, Q.; Jia, L.; Fan, L.; Huang, Y. Synthesis and antiproliferative activity of some steroidal thiosemicarbazones, semicarbazones and hydrozones. *Steroids* 2014, *87*, 99–107. [CrossRef] [PubMed]
- Khan, S.A.; Asiri, A.M. Synthesis and spectroscopic studies of Ru(II) complexes of steroidal thiosemicarbazones by multi step reaction: As anti-bacterial agents. *Steroids* 2017, 124, 23–28. [CrossRef] [PubMed]
- 24. Loncle, C.; Brunel, J.M.; Vidal, N.; Dherbomez, M.; Letourneux, Y. Synthesis and antifungal activity of cholesterol-hydrazone derivatives. *Eur. J. Med. Chem.* 2004, 39, 1067–1071. [CrossRef] [PubMed]
- Merlani, M.I.; Amiranashvili, L.S.; Mulkidzhanyan, K.G.; Shelar, A.R.; Manvi, F.V. Synthesis and antituberculosis activity of certain steroidal derivatives of the 5α –series. *Chem. Nat. Compd.* 2008, 44, 618–620. [CrossRef]
- Merlani, M.I.; Amiranashvili, L.S.; Kemertelidze, E.O.; Mulkidzhanyan, K.G. Synthesis and antimicobacterial activity of some steroidal derivatives of tigogenin. *Chem. Nat. Compd.* 2009, 45, 389–392. [CrossRef]
- 27. Shelar, A.R.; Merlani, M.; Shelar, M.; Amiranashvili, L.; Shelar, B. Medicinal Applications of Benzoic Acid Hydrazones Synthesized on the Basis of Steroidal Tigogenin. U.S. PATENT 8623849B2, 7 January 2014.
- Nadaraia, N.S.; Amiranashvili, L.S.; Merlani, M.; Kakhabrishvili, M.I.; Barbakadze, N.N.; Geronikaki, A.; Petrou, A.; Poroikov, V.; Ciric, A.; Glamoclija, J.; et al. Novel antimicrobial agents' discovery among the steroid derivatives. *Steroids* 2019, 144, 52–65. [CrossRef]
- Amiranashvili, L.; Nadaraia, N.; Merlani, M.; Kamoutsis, C.; Petrou, A.; Geronikaki, A.; Pogodin, P.; Druzhilovskiy, D.; Poroikov, V.; Ciric, A.; et al. Antimicrobial Activity of Nitrogen-Containing 5-α-Androstane Derivatives: In Silico and Experimental Studies. *Antibiotics* 2020, 9, 224. [CrossRef]
- Lagunin, A.; Stepanchikova, A.; Filimonov, D.; Poroikov, V. PASS: Prediction of activity spectra for biologically active substances. Bioinformatics 2000, 16, 747–748. [CrossRef]
- 31. Kartsev, V.; Lichitsky, B.; Geronikaki, A.; Petrou, A.; Smiljkovic, M.; Kostic, M.; Radanovic, O.; Soković, M. Design, synthesis and antimicrobial activity of usnic acid derivatives. *MedChemComm* **2018**, *9*, 870–882. [CrossRef]
- Haroun, M.; Tratrat, C.; Kositsi, K.; Tsolaki, E.; Petrou, A.; Aldhubiab, B.; Attimarad, M.; Harsha, S.; Geronikaki, A.; Venugopala, K.N.; et al. New Benzothiazole-based Thiazolidinones as Potent Antimicrobial Agents. Design, synthesis and Biological Evaluation. *Curr. Top. Med. Chem.* 2018, 18, 75–87. [CrossRef] [PubMed]
- 33. Kritsi, E.; Matsoukas, M.T.; Potamitis, C.; Detsi, A.; Ivanov, M.; Sokovic, M.; Zoumpoulakis, P. Novel Hit Compounds as Putative Antifungals: The Case of Aspergillus fumigatus. *Molecules* **2019**, *24*, 3853. [CrossRef] [PubMed]
- Clinical and Laboratory Standards Institute—CLSI. Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically. Approv. Stand. 2009, 29, 1–65.
- Horishny, V.; Kartsev, V.; Matiychuk, V.; Geronikaki, A.; Anthi, P.; Pogodin, P.; Poroikov, V.; Ivanov, M.; Kostic, M.; Soković, M.D.; et al. 3-Amino-5-(indol-3-yl)methylene-4-oxo-2-thioxothiazolidine Derivatives as Antimicrobial Agents: Synthesis, Computational and Biological Evaluation. *Pharmaceuticals* 2020, 13, 229. [CrossRef] [PubMed]
- Smiljkovic, M.; Matsoukas, M.T.; Kritsi, E.; Zelenko, U.; Grdadolnik, S.G.; Calhelha, R.C.; Ferreira, I.C.F.R.; Sankovic-Babic, S.; Glamoclija, J.; Fotopoulou, T.; et al. Nitrate Esters of Heteroaromatic Compounds as Candida albicans CYP51 Enzyme Inhibitors. *ChemMedChem* 2018, 13, 251–258. [CrossRef]

- Fesatidou, M.; Zagaliotis, P.; Camoutsis, C.; Petrou, A.; Eleftheriou, P.; Tratrtat, C.; Haroun, M.; Geronikaki, A.; Ciric, A.; Sokovic, M. 5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation. *Bioorg. Med. Chem.* 2018, 26, 4664–4676. [CrossRef]
- 38. Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. *Drug Discov. Today Technol.* **2004**, *1*, 337–341. [CrossRef]
- 39. SwissADME Program. Available online: https://swissadme.ch (accessed on 19 October 2022).

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.